Abstract
Background
Digital mental health technologies (DMHTs) have the potential to enhance mental health care delivery. However, there is little information on how DMHTs are evaluated and what factors influence their use.
Objective
A systematic literature review was conducted to understand how DMHTs are valued in the United States from user, payer, and employer perspectives.
Methods
Articles published after 2017 were identified from MEDLINE, Embase, PsycINFO, Cochrane Library, the Health Technology Assessment Database, and digital and mental health congresses. Each article was evaluated by 2 independent reviewers to identify US studies reporting on factors considered in the evaluation of DMHTs targeting mental health, Alzheimer disease, epilepsy, autism spectrum disorder, or attention-deficit/hyperactivity disorder. Study quality was assessed using the Critical Appraisal Skills Program Qualitative and Cohort Studies Checklists. Studies were coded and indexed using the American Psychiatric Association’s Mental Health App Evaluation Framework to extract and synthesize relevant information, and novel themes were added iteratively as identified.
Results
Of the 4353 articles screened, data from 26 unique studies from patient, caregiver, and health care provider perspectives were included. Engagement style was the most reported theme (23/26, 88%), with users valuing DMHT usability, particularly alignment with therapeutic goals through features including anxiety management tools. Key barriers to DMHT use included limited internet access, poor technical literacy, and privacy concerns. Novel findings included the discreetness of DMHTs to avoid stigma.
Conclusions
Usability, cost, accessibility, technical considerations, and alignment with therapeutic goals are important to users, although DMHT valuation varies across individuals. DMHT apps should be developed and selected with specific user needs in mind.
Reference51 articles.
1. Content of premarket submissions for device software functions: guidance for industry and Food and Drug Administration staffU.S. Food and Drug Administration20236142024-07-19https://www.fda.gov/media/153781/download
2. Characteristics and challenges of the clinical pipeline of digital therapeutics
3. Policy for device software functions and mobile medical applications: guidance for industry and Food and Drug Administration staffU.S. Food and Drug Administration2023-01-06https://www.fda.gov/media/80958/download
4. Smartphone Apps for College Mental Health: A Concern for Privacy and Quality of Current Offerings
5. Augmenting Mental Health in Primary Care: A 1-Year Study of Deploying Smartphone Apps in a Multi-site Primary Care/Behavioral Health Integration Program